Hims & Hers Opens $149 Wegovy & Ozempic Waitlist via Novo Nordisk Deal
Hims & Hers Health (NYSE: HIMS) has launched a waitlist for branded Wegovy and Ozempic at just $149, partnering directly with Novo Nordisk to expand access to these blockbuster GLP-1 receptor agonists. This move focuses on long-term care and outcomes for patients seeking effective weight-loss therapy, addressing supply shortages and high costs that have limited availability. As demand for semaglutide-based medications like Ozempic and Wegovy surges, this initiative could reshape telehealth delivery of metabolic health treatments.
What Are Wegovy and Ozempic? A Quick Primer on GLP-1 Medications
Wegovy (semaglutide 2.4 mg weekly) and Ozempic (semaglutide up to 2 mg weekly, primarily for type 2 diabetes with off-label weight-loss use) are GLP-1 receptor agonists. These injectable peptides mimic the glucagon-like peptide-1 hormone, slowing gastric emptying, reducing appetite, and improving insulin sensitivity. Clinical trials like STEP for Wegovy showed average 15-20% body weight loss over 68 weeks, making them cornerstones of obesity management alongside diet and exercise.
Why does expanded access matter? List prices exceed $1,300/month without insurance, but compounded versions faced FDA scrutiny in 2024. Branded options via Hims & Hers at $149 represent a cash-pay breakthrough, potentially eligible for some insurances later. Patients should consult providers to assess suitability, especially with BMI ≥30 or ≥27 with comorbidities.
The Hims & Hers-Novo Nordisk Partnership: Expanding Access to Weight-Loss Drugs
This deal allows Hims & Hers to offer authentic, FDA-approved Wegovy and Ozempic through their platform, starting with a waitlist due to limited supply. It emphasizes long-term outcomes, integrating virtual consultations, dosing guidance, and monitoring. For patients, this means clinician-prescribed therapy shipped discreetly, with tools like symptom trackers (e.g., Shotlee apps) aiding adherence and side effect management such as nausea or GI upset.
Compared to alternatives like Eli Lilly's Zepbound (tirzepatide), semaglutide remains dominant with proven cardiovascular benefits from trials like SELECT, reducing major adverse events by 20%. Safety profiles include thyroid risks (black box warning) and pancreatitis—discuss with doctors if history applies.
HIMS Stock Technical Analysis
HIMS is trading 31.2% above its 20-day SMA but 21.7% below its 100-day SMA, and shares are down 20.67% over the past 12 months, which fits a "bounce inside a bigger downtrend" profile. Within the $13.74 to $70.43 52-week range, the stock is positioned closer to its lows than its highs, and the 50-day SMA remains below the 200-day SMA after the death cross in December.
RSI is at 62.69, in neutral territory, suggesting the recent rebound hasn't reached overheated levels. The MACD is bullish, with the MACD line at 0.6719 above the signal line at -0.7768, and the positive histogram (1.4488) shows that upside momentum has been improving.
The combination of an RSI above 50 and a bullish MACD suggests mixed momentum, with short-term strength battling a weaker longer-term trend.
Price Action Snapshot
HIMS Stock Price Activity: Hims & Hers Health shares were down 3.76% at $24.04 at the time of publication on Wednesday, according to Benzinga Pro data.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
Earnings & Analyst Outlook for Hims & Hers Health
Looking further out, the next major catalyst for the stock arrives with the May 4, 2026 (estimated) earnings report.
- EPS Estimate: 2 cents (Down from 20 cents YoY)
- Revenue Estimate: $618.44 million (Up from $586.01 million YoY)
- Valuation: P/E of 49.0x (Indicates premium valuation relative to peers)
Analyst Consensus & Recent Actions: The stock has a Hold rating and an average price target of $31.23. Recent analyst moves include:
- Leerink Partners: Market Perform (Raises Target to $25.00) (Mar. 16)
- Barclays: Overweight (Raises Target to $29.00) (Mar. 11)
- Citigroup: Upgraded to Neutral (Raises Target to $24.00) (Mar. 10)
Benzinga Edge Rankings and ETF Exposure
Below is the Benzinga Edge scorecard for Hims & Hers Health, highlighting its strengths and weaknesses compared to the broader market:
[Note: In a full article, embed Benzinga Edge image or table here.]
The Verdict: Hims & Hers Health. Benzinga Edge's signal reveals a premium-valued setup with weak momentum and only moderate growth support. For longer-term bulls, the chart needs to hold the $24.00 area and keep rebuilding above the 50-day trend before the move looks more durable.
Top ETF Exposure: Significance: Because HIMS carries meaningful weight in these funds, any significant inflows or outflows for these ETFs will likely force automatic buying or selling of the stock.
Practical Guidance for Patients Interested in Wegovy or Ozempic via Hims & Hers
Join the waitlist on the Hims & Hers platform after a virtual consult. Start low (0.25 mg weekly) to minimize side effects like nausea, progressing as tolerated. Monitor with apps for symptoms; combine with 500-calorie deficit diet and 150 min/week exercise for optimal results. Not for cosmetic use—FDA-approved for chronic weight management.
Comparisons: Vs. oral Rybelsus (semaglutide), injectables yield superior loss. Vs. generics, branded ensures potency amid compounding concerns.
Key Takeaways: What This Means for Patients and Investors
- Patient Access: $149 branded GLP-1s via telehealth lower barriers, prioritizing outcomes.
- Stock Outlook: Short-term bounce potential, but hold $24+ for durability amid Hold consensus.
- Health Impact: GLP-1s transform metabolic health; consult MD for personalization.
In conclusion, Hims & Hers' Novo deal boosts GLP-1 availability while HIMS stock navigates volatility. Patients: Check eligibility today. Investors: Watch earnings and technicals closely.
